Last reviewed · How we verify
Oral IR-LD/CD
Oral IR-LD/CD is a levodopa/carbidopa combination that increases dopamine levels in the brain by delivering levodopa with carbidopa, a decarboxylase inhibitor, to treat motor symptoms of Parkinson's disease.
Oral IR-LD/CD is a levodopa/carbidopa combination that increases dopamine levels in the brain by delivering levodopa with carbidopa, a decarboxylase inhibitor, to treat motor symptoms of Parkinson's disease. Used for Parkinson's disease motor fluctuations and wearing-off phenomena.
At a glance
| Generic name | Oral IR-LD/CD |
|---|---|
| Also known as | IR-LD/CD |
| Sponsor | NeuroDerm Ltd. |
| Drug class | Dopamine replacement therapy |
| Target | Dopamine pathway; aromatic amino acid decarboxylase inhibition |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine by aromatic amino acid decarboxylase. Carbidopa is a peripheral decarboxylase inhibitor that prevents premature conversion of levodopa in the periphery, allowing more levodopa to reach the brain. The immediate-release formulation with low-dose carbidopa provides rapid symptom relief for Parkinson's motor fluctuations.
Approved indications
- Parkinson's disease motor fluctuations and wearing-off phenomena
Common side effects
- Dyskinesia
- Motor fluctuations
- Nausea
- Dizziness
- Orthostatic hypotension
Key clinical trials
- Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (PHASE3)
- A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease (PHASE2)
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations (PHASE3)
- Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study (PHASE3)
- A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral IR-LD/CD CI brief — competitive landscape report
- Oral IR-LD/CD updates RSS · CI watch RSS
- NeuroDerm Ltd. portfolio CI